Trials / Unknown
UnknownNCT04676997
Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)
A Phase Ⅱ Study to Evaluate Efficacy and Safety of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Shandong Cancer Hospital and Institute · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of Camrelizumab Combination With Nab-Paclitaxel and Epirubicin as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Camrelizumab | 200mg on days1,15 of Cycles 1-4 (Q2W); IV infusion. 200mg on day 1 of Cycles 5-8 (Q2W); IV infusion. |
| DRUG | Nab paclitaxel | 125 mg/m² on day 1, 8 and 15 of Cycles 1-4 (QW 3/4); IV infusion. |
| DRUG | Epirubicin | 90 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion. |
| DRUG | Cyclophosphamide | 600 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion. |
Timeline
- Start date
- 2020-05-20
- Primary completion
- 2021-07-30
- Completion
- 2024-02-28
- First posted
- 2020-12-21
- Last updated
- 2020-12-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04676997. Inclusion in this directory is not an endorsement.